Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel)
Main Authors: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7766528/
https://ncbi.nlm.nih.gov/pubmed/33339404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13120470
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items